Author: Leander, R. N.; Wu, Y.; Ding, W.; Nelson, D. E.; Sinkala, Z.
Title: A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium Cord-id: 7n2z7lm7 Document date: 2021_8_11
ID: 7n2z7lm7
Snippet: We present a differential equation model of the innate immune response to SARS-CoV-2 within the alveolar epithelium. Critical determinants of the viral dynamics and host response, including type I and type II alveolar epithelial cells, interferons, chemokines, toxins and innate immune cells, are included. We estimate model parameters, compute the within-host basic reproductive number, and study the impacts of therapies, prophylactics, and host/pathogen variability on the course of the infection.
Document: We present a differential equation model of the innate immune response to SARS-CoV-2 within the alveolar epithelium. Critical determinants of the viral dynamics and host response, including type I and type II alveolar epithelial cells, interferons, chemokines, toxins and innate immune cells, are included. We estimate model parameters, compute the within-host basic reproductive number, and study the impacts of therapies, prophylactics, and host/pathogen variability on the course of the infection. Model simulations indicate that the innate immune response suppresses the infection and enables the alveolar epithelium to partially recover. While very robust antiviral therapy controls the infection and enables the epithelium to heal, moderate therapy is of limited benefit. Meanwhile interferon therapy is predicted to reduce viral load but exacerbate tissue damage. The deleterious effects of interferon therapy are especially apparent late in the infection. Individual variation in ACE2 expression, epithelial cell interferon production, and SARS-CoV-2 spike protein binding affinity are predicted to significantly impact prognosis.
Search related documents:
Co phrase search for related documents- acute respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory distress syndrome and additional support: 1, 2, 3, 4
- acute respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
- acute respiratory distress syndrome and low plateau: 1, 2, 3, 4, 5, 6, 7
- acute respiratory distress syndrome and lung alveolar region: 1
- acute respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory distress syndrome and lung fluid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- acute respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- adaptive immune response and administration route: 1, 2
- adaptive immune response and low density: 1
- adaptive immune response and low number: 1
- adaptive immune response and lps challenge: 1
- adaptive immune response and lung epithelial cell: 1
- adaptive immune response and lung fluid: 1
- adaptive immune response and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adaptive immune response and lung pathology: 1, 2, 3, 4
- adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
- adaptive immune response and macrophage response: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date